Iambic Appoints Nicholas A. Saccomano, Ph. D., to its Scientific Advisory Board

This is some text inside of a div block.
February 4, 2022

SAN DIEGO, CA – Entos, Inc. (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthesis to design small-molecule therapeutics, today announced that it has appointed Nicholas Saccomano, Ph.D., to the Company’s Scientific Advisory Board (“SAB”) effective January 10, 2022.

“Nick is a seasoned biopharmaceutical executive with nearly 35 years of R&D experience across a broad spectrum of therapeutic areas and modalities,” said Entos Co-Founder and Chief Executive Officer, Tom Miller, Ph.D.  “One of our greatest strengths at Entos is our stellar Scientific Advisory Board, and the addition of Nick Saccomano only makes it stronger.  We look forward to continuing our work to build out our talented team, accelerate molecular discovery and revolutionize the process of drug development as we benefit from the guidance and capabilities of Nick and our entire SAB.”

Dr. Saccomano currently serves as a scientific advisor to several innovative life sciences companies.  He previously served as Chief Scientific Officer and Site Head of the Boulder facility for Pfizer R&D Inc., leading a 170-person R&D team that advanced a portfolio of small molecule drug programs from inception to proof-of-concept.  Prior to his time at Pfizer, Nicholas served as Chief Science Officer at Array Biopharma Inc., where he and his team created and advanced ten clinical-stage compounds.  Before Array, Dr. Saccomano served spent time at SomaLogic Inc. as Chief Technology Officer, managing scientific and technical teams advancing elements of the company’s proteomic platform. Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University.

“Throughout my career, the immensely complex nature of drug development and discovery has dealt with two major headwinds: high costs and inefficient time usage,” said Nicholas Saccomano, Ph.D.  “With this in mind, I’m excited by the team at Entos because they’re doing something about it.  The Entos technology will result in faster timelines and improved therapeutic outcomes, and I’m proud to work with them as they revolutionize the drug discovery process.”

About Entos

Founded in 2019 and headquartered in San Diego, California, Entos is focused on disrupting therapeutic discovery with its cutting-edge platform that uses AI-driven automated synthesis to rapidly design small-molecule therapeutics. Leveraging breakthrough technology from Caltech and the University of Bristol, the Entos team is comprised of renowned scientists and engineers with world-class expertise in machine learning, medicinal chemistry, high-throughput experimentation, and drug discovery. Learn more about Entos' industry-revolutionizing platform at www.entos.ai.

Media Contacts

TJ White

Sard Verbinnen & Co.


Media Contacts